1	Nationally representative prevalence and determinants of post-acute
2	sequelae of SARS-CoV-2 infection (Long COVID) amongst Mexican adults in
3	2022
4	Omar Yaxmehen Bello-Chavolla ^{1*} , Carlos A. Fermín-Martínez ^{1,2*} , Luisa Fernández-
5	Chirino ¹ , Daniel Ramírez-García ^{1,3} , Arsenio Vargas-Vázquez ³ , Martín Roberto Basile-
6	Alvarez ^{1,3} , Paulina Sánchez Castro ^{1,3} , Alejandra Núñez-Luna ^{1,3} , Neftali Eduardo Antonio-
7	Villa ⁴
8	*These authors contributed equally to the drafting of this work
9	
10	¹ Research Division, Instituto Nacional de Geriatría, Mexico City, Mexico. ² MD/PhD
11	(PECEM) Program, Facultad de Medicina, Universidad Nacional Autónoma de México,
12	Mexico City, Mexico. ³ Facultad de Medicina, Universidad Nacional Autónoma de México,
13	Mexico City, Mexico. ⁴ Department of Endocrinology, Instituto Nacional de Cardiología
14	Ignacio Chávez, Mexico City, Mexico.
15	
16	
17	
18	
19	Correspondence:
20	Omar Yaxmehen Bello-Chavolla. Division of Research. Instituto Nacional de Geriatría.
21	Anillo Perif. 2767, San Jerónimo Lídice, La Magdalena Contreras, 10200, Mexico City,
22	Mexico. Phone: +52 (55) 5548486885. E-mail: oyaxbell@yahoo.com.mx
23	
24	
25	

26 **CONFLICT OF INTERESTS:** The authors declare that they have no conflict of interests.

- 4,049 text words; 44 references; 4 figures, 1 tables.
- 28 **<u>Running headline</u>**: Long COVID prevalence and determinants in Mexico
- 29 ABSTRACT (248 WORDS)
- 30 **OBJECTIVE:** To characterize the epidemiology of post-acute sequelae after SARS-CoV-2

infection (PASC) in Mexico during 2022 and identify potential predictors of PASC
 prevalence using nationally representative data.

METHODS: We analyzed data from the 2022 Mexican National Health and Nutrition Survey (ENSANUT) totaling 24,434 participants, representing 85,521,661 adults ≥20 years. PASC was defined using both the World Health Organization definition and a PASC score ≥12. Estimates of PASC prevalence were stratified by age, sex, rural vs. urban setting, social lag quartiles, number of reinfections, vaccination status and by periods of predominance of SARS-CoV-2 circulating variants. Predictors of PASC were assessed using logistic regression models adjusted by survey weights.

40 **RESULTS:** Persistent symptoms after SARS-CoV-2 infection were reported by 12.44% (95%CI 11.89-12.99) of adults ≥20 years in Mexico during 2022. The most common 41 persistent symptoms were musculoskeletal pain, headache, cough, loss of smell or taste, 42 fever, post-exertional malaise, brain fog, anxiety, chest pain, and sleep disorders. PASC 43 44 was present in 21.21% (95%CI 7.71-9.65) subjects with previously diagnosed COVID-19. Over 28.6% patients with PASC reported symptoms persistence ≥6 months and 14.05% 45 reported incapacitating symptoms. Higher PASC prevalence was associated with SARS-46 CoV-2 reinfections, depressive symptoms and living in states with high social lag. PASC 47 prevalence, particularly its more severe forms, decreased with COVID-19 vaccination and 48 for infections during periods of Omicron variant predominance. 49

- 50 **CONCLUSIONS:** PASC implies a significant public health burden in Mexico as the
- 51 COVID-19 pandemic transitions into endemicity. Promoting reinfection prevention and
- 52 booster vaccination may be useful to reduce PASC burden.
- 53 Keywords: Long COVID; PASC; Mexico; COVID-19; sequelae

55 **INTRODUCTION**

Post-acute persistent symptoms of severe acute coronavirus 2 (SARS-CoV-2) infection 56 57 remain a challenge to reduce the burden of SARS-CoV-2 in affected patients as the 58 coronavirus disease (COVID-19) pandemic progresses towards endemicity (1). The definition of post-acute sequelae after SARS-CoV-2 infection (PASC) is still evolving given 59 60 heterogeneous patient profiles, with other terms also recognizing it as post-acute COVID-19 condition, long COVID, and post-acute COVID-19 syndrome (2). A Delphi consensus 61 62 by the World Health Organization defined it as a condition affecting individuals with suspected or confirmed SARS-CoV-2 infection exhibiting persistent symptoms lasting for 63 at least two months without an alternative pathophysiological explanation (3). Recently, 64 65 Thaweethai et al. developed a self-reported symptom-based definition to better 66 characterize persistent COVID-19 symptoms across cohorts and provide another overview of the epidemiology of PASC (4). To this date, reports on the epidemiology of persistent 67 68 symptoms are scarce, particularly in Latin American countries, which hinders recognition 69 of the magnitude of the problem and implementation of public policies aimed at reducing PASC burden (5). 70

Mexico is one of the countries with the highest morbidity and mortality related to COVID-19 71 72 world-wide (6). A landscape of high cardio-metabolic burden with marked social 73 inequalities increased the impact of the pandemic and led to sustained excess deaths, which were ameliorated with the availability of vaccines (7-9). Despite the well-74 characterized acute impact of the SARS-CoV-2 pandemic in low- and middle-income 75 settings, information regarding the impact of debilitating chronic sequelae of SARS-CoV-2 76 77 infection in these settings is lacking. In Mexico, few reports have evaluated the impact of 78 PASC, particularly focusing on cases with severe COVID-19 (10,11). However, nationally representative estimates of persistent COVID-19 symptoms and particularly PASC as 79

defined by current criteria in Mexico remain unreported. Here, we aimed to estimate the prevalence of persistent COVID-19 symptoms and post-acute sequelae of SARS-CoV-2 infection (PASC) using a nationally representative sample of Mexican adults for the year 2022. We also aimed to evaluate potential correlates of PASC prevalence including sociodemographic and infection-related determinants to characterize vulnerable groups and potential areas of intervention to ameliorate the long-term burden of COVID-19 in Mexico.

87 METHODS

88 <u>Study design</u>

We analyzed data from the Mexican National Health and Nutrition Survey (ENSANUT) for 89 90 the year 2022. Briefly, ENSANUT is a population-based survey that aims to assess the 91 health and nutritional status of Mexican adults. ENSANUT is representative at a national, regional, and rural/urban level, as it uses two-stage probabilistic cluster stratified sampling 92 93 based on households and individuals. Participants underwent a comprehensive questionnaire collecting demographic, socioeconomic, and health-related data, and a 94 physical exam including measurement of blood pressure and anthropometry. ENSANUT 95 2022 was collected from July to December 2022 in 10,160 households (response rate of 96 97 73%) which amounts to 11,472 complete interviews in adults \geq 20 years old (12). This 98 survey additionally aimed to investigate health and well-being of Mexican adults during the COVID-19 pandemic and a random subsample of 5,971 adults ≥20 years old provided a 99 capillary blood sample to detect antibodies for SARS-CoV-2 infection. A second 100 101 subsample (n=2,092) had an additional biochemical evaluation with venous blood samples 102 for glycated hemoglobin (HbA1c), fasting glucose, and a fasting lipid profile. A complete 103 flowchart of participant selection is outlined in Supplementary Materials.

104 SARS-CoV-2 seroprevalence

Seropositivity to SARS-CoV-2 was evaluated using an Elecsys detection assay for IgG against the N-protein (SARS-CoV-2 Nucleocapsid, #09 203 079 190, Roche-N) validated by the Institute for Epidemiological and Diagnostic Reference. Samples were considered positive if quantification was \geq 0.72.0 U/ml (13). COVID-19 seroprevalence was estimated using population sample weights with the *survey* R package.

- 110 Variable definitions
- 111 *Persistent COVID-19 symptoms*

Previously diagnosed COVID-19 was defined by self-report among individuals who 112 113 answered, "at least once" to the question: "Since February 2020, how many times have 114 you been diagnosed with COVID-19 by health personnel?" Amongst individuals with at 115 least one previous COVID-19 diagnosis, persistent symptoms after SARS-CoV-2 infection 116 were asked (3) using the question: "Regarding the last time you had COVID, did you 117 continue to present any of these symptoms / sequelae one month after your illness 118 began?" and interrogated the presence of the following symptoms: cough, fatigue or 119 tiredness, anxiety, depression, fever, difficulty sleeping, kidney complications, loss of appetite, weight loss, headache, dizziness, muscle or joint pain, difficulty breathing 120 (dyspnea), shortness of breath, chest pain, vomiting or diarrhea (gastrointestinal 121 122 symptoms), loss or decrease in smell, loss or decrease in taste, difficulty thinking or 123 concentrating or other symptoms, including post-exertional malaise, which we defined as symptoms which worsen with activity and impede normal functioning. Participants were 124 also asked to clarify if the symptoms persisted for less than an additional month, from one 125 126 to three months, from three to six months, more than 6 months, or are still present.

127 Post-acute COVID-19 sequelae

We used the definition reached by Delphi consensus from the World Health Organization, which defines PASC, which defines it as the presence of at least one persistent symptom,

130 in individuals with previously diagnosed SARS-CoV-2 infection, and which referred 131 persistent symptoms lasting ≥3 months from the previous COVID-19 diagnosis. Based on 132 this, we classified persistent symptoms into subacute or ongoing symptomatic COVID-19. 133 defined as the presence of any persistent symptom 4-12 weeks beyond acute COVID-19 and PASC(14). Furthermore, based on a recent definition by Thaweethai et al. we 134 135 calculated the PASC score, which defined the presence of PASC with a score ≥12 points to assess its prevalence in this population (4). Symptoms such as palpitations, chronic 136 thirst, decreased sexual desire or capacity, or abnormal movements were not considered 137 in ENSANUT 2022 and were not included for score calculation. This complementary 138 definition was included as a sensitivity analysis and was considered irrespective of 139 140 symptom duration.

141 *Modifying factors*

We evaluated age categories of 10-year intervals (20-29, 30-39, 40-49, 50-59, 60-69 or
≥70 years), sex, rural/urban area, smoking status and presence of diabetes and
hypertension as modifying factors of PASC prevalence. The following factors were also
considered to evaluate components of SARS-CoV-2 infection:

- SARS-CoV-2 reinfection Defined as having been diagnosed with COVID-19
 more than one time by healthcare personnel (self-report).
- Predominant SARS-CoV-2 variants SARS-CoV-2 infection was assumed to be
 most likely caused by the predominant variant based on the date of symptom
 onset. Based on data submitted to GISAID (48), from March 3rd, 2020, until
 December 30th, 2020, the predominant SARS-CoV-2 variant was the ancestral
 strain, followed by the predominance of the B.1.1.519 variant until June 6th, 2021,
 the B.1.617.2 (Delta) variant until December 6th, 2021. B.1.1.529.1 (Omicron)
 subvariant was considered predominant from December 7th, 2022, onwards (15).

155 For modeling, COVID-19 were classified into those likely caused by the Omicron 156 variant or otherwise.

- COVID-19 vaccination Vaccination was defined by self-report among individuals
 who answered "yes" to the question: "Have you been vaccinated for COVID-19?"
 and further questioned if receiving one, two, three or four vaccine doses.
- 160 Social lag - We used data from the National Council for Evaluation of Social ٠ Development Policy (CONEVAL), which provides state-level estimates of the 2020 161 social lag index (SLI), which is a composite measure of access to education, health 162 163 care, dwelling quality, and basic services in Mexico (16). To assess marginalization 164 independently of urbanization, we extracted mean population density from each 165 state and regressed it onto SLI and obtained the residuals which represent a 166 density-independent social lag index (DISLI) (9,17,18). We then categorized states 167 into DISLI guartiles (Q1-Q4) and classified individuals from each guartile to each 168 according to their state of residence.
- Depressive symptoms Evaluated using he seven-item version of the Center for
 Epidemiologic Studies Depression Scale (CESD-7). CESD-7 measures the
 frequency with which depressive symptoms are experienced during the week prior
 to the interview collected at ENSANUT 2022. Cut-offs to identify the presence of
 moderate or severe depressive symptoms were ≥9 points for adults aged 20-59,
 and ≥5 points for adults ≥60 years (19,20).
- Incapacitating symptoms Defined if the person answered "yes" to the question
 "Do these [persistent COVID-19] symptoms prevent you or did they prevent you
 from taking care of yourself? For example, that difficulties to bathe or dress
 oneself".
- 179 <u>Statistical analyses</u>

180 Weighted prevalence of PASC and persistent COVID-19 symptoms

181 Prevalence of PASC and persistent symptoms were estimated using sample weights from 182 ENSANUT for participants ≥20 years, as well as those with SARS-CoV-2 seropositivity 183 and for the population with previously diagnosed COVID-19; all estimations were conducted using the survey R package (21). We further performed weighted subgroup 184 185 estimation for prevalence trends stratified by age category, sex, geographical region, previous reinfection, vaccination status, infection during periods of Omicron variant 186 187 predominance, indigenous identity, rural or urban area, and DISLI category (high or low/middle). 188

189 Predictors of PASC prevalence

To identify correlates of PASC positivity we fitted fixed effects logistic regression models considering survey weights amongst individuals with previously diagnosed COVID-19 and complete data including comorbidities. A sensitivity analysis was conducted exploring predictors for any sequelae present compared to the PASC definition. All statistical analyses were conducted using R version 4.1.2 and p-values thresholds are estimated for a two-sided significance level of $\alpha = 0.05$.

196 **RESULTS**

197 <u>Study population</u>

We included adults aged ≥20 years old who completed the health questionnaire, totaling 24,434 participants (expanded to 85,521,661 adults); amongst them, 4,898 participants were selected for capilar blood sampling to estimate SARS-CoV-2 seropositivity (expanded to 85,098,924 adults). A flowchart diagram detailing the participant selection process is available in **Supplementary Figure 1**. Overall, we identified a prevalence of previously diagnosed COVID-19 amongst adults ≥20 years of 22.0% (95%Cl 21.31-22.69), which contrasted markedly with the seroprevalence of IgG against the N-protein of SARS-

CoV-2, estimated at 93.66% (95%CI 92.78-94.54). Overall, approximately 86.21% (95%CI
85.64-86.78) of adults had received at least one dose of COVID-19 vaccines, with 11.62%
(95%CI 11.1-12.14) receiving only one dose, 29.6% (95%CI 28.83-30.37) with two doses,
39.51% (95%CI 38.73-40.29) with three doses and 5.48% (95%CI 5.11-5.85) with four
doses.

210 <u>Prevalence of persistent COVID-19 symptoms</u>

211 Overall, we identified that 12.44% (95%CI 11.89-12.99) of adults ≥20 years had at least 212 one persistent COVID-19 symptom for ≥ 1 month, which equates to a total of 10,634,663 213 individuals (95%CI 10,155,424-11,113,902). Amongst them, 45.87% (95%CI 43.49-48.25) 214 lasted <1 additional month, 16.74% (95%Cl 14.93-18.55) persisted between 1-3 months, 215 4.54% (95%CI 3.56 -5.52) between 3-6 months, 4.26% (95%CI 3.28-5.24) for >6 months 216 and 28.6% (95%CI 26.43-30.77) persisting until the date of the interview. The prevalence 217 of any persistent symptoms was similar when analyzing only N-protein seropositive adults 218 (12.7%, 95%CI 11.48-14.06) and was higher when considering only cases with previously 219 diagnosed COVID-19 by a physician (56.52%, 95%CI 54.75-58.29). The ten most frequent persistent symptoms amongst subjects with SARS-CoV-2 N-protein seropositivity were 220 musculoskeletal pain, headache, cough, loss of smell or taste, fever, post-exertional 221 222 malaise, brain fog, anxiety, chest pain, and sleep disorders (Supplementary Material).

223 <u>Persistent symptoms in selected subgroups</u>

Amongst SARS-CoV-2 N-protein seropositive individuals subacute or ongoing symptomatic COVID-19 was present in 7.42% (95%CI 6.42-8.42), whilst PASC was present in 5.51% (95%CI 4.61-6.41) of cases (**Figure 1**). The five most common persistent symptoms in subacute COVID-19 were cough, headache, fever, musculoskeletal pain, and loss of smell or taste, whilst for PASC they were musculoskeletal pain, post-exertional malaise, headache, cough, and dyspnea (**Figure 1A-B**). Regarding sex, the prevalence of

230 any persistent symptom amongst SARS-CoV-2 N-protein seropositive individuals was higher for males (14.12%, 95%CI 12.42-15.85) compared to females (10.50%, 95%CI 231 232 8.56-12.44); in males the five most frequent persistent symptoms were headache, 233 musculoskeletal pain, and cough, whilst for females they were cough, musculoskeletal pain, and fever (Supplementary Material). In cases with previously diagnosed COVID-19 234 235 SARS-CoV-2 primoinfection was associated with lower prevalence of persistent sequelae (55.39%, 95%CI 53.49-57.29) compared to cases with at least one SARS-CoV-2 236 reinfection (64.41%, 95%CI 59.69-69.13); in cases with SARS-CoV-2 primoinfection the 237 238 most common persistent symptoms were musculoskeletal pain, headache, cough, postexertional malaise, and loss of smell or taste, whilst for reinfection they were cough, 239 240 headache, post-exertional malaise, musculoskeletal pain, and fever (Supplementary 241 Material).

242 <u>Prevalence of PASC in Mexico</u>

243 Using the WHO definition, we identified a prevalence of 4.67% (95%CI 4.32-5.02) in the 244 overall population, 5.51% (95%CI 4.61-6.41) amongst SARS-CoV-2 N-protein seropositive population, and 21.21% (95%CI 19.74-22.68) in subjects with previously diagnosed 245 246 COVID-19, totaling 3,990,011 affected adults (95%CI 3,685,878-4,294,144; 247 Supplementary Material). We identified the highest prevalence of PASC amongst 248 subjects with previously diagnosed COVID-19 in Mexico City/Mexico State and the Peninsula region, whilst the lowest prevalence was observed in the US Border region, 249 250 coincidentally most clustering in Northern Mexico (Figure 2A). When comparing 251 characteristics between individuals with and without PASC, we identified that individuals 252 with PASC clustered most persistent symptoms, even those not included in the PASC 253 score; furthermore, higher rates of reinfections, diabetes and hypertension were observed 254 individuals with PASC (Table 1). Overall, 15.13% (95%CI 13.50-16.76) of individuals

255 affected by persistent symptoms reported incapacity to perform everyday tasks including take care of oneself; this rate was 14.06% (95%CI 11.37-16.75) amongst PASC compared 256 257 to 7.13% (95%CI 6.17-8.09) in individuals without PASC who had previously diagnosed 258 with COVID-19, indicating a high burden of PASC on everyday functioning. Finally, we analyzed cases with PASC score ≥12, observing a prevalence of 1.91% (95%CI 1.69-259 260 2.13) in the general population, 2.02% (95%CI 1.48-2.56) in SARS-CoV-2 N-protein seropositive individuals and 8.68% (95%CI 7.72-9.65) in individuals with previously 261 diagnosed SARS-CoV-2 infection. Notably, incapacitating PASC symptoms were observed 262 263 in 45.38% (95%CI 39.65-51.11) of subjects with PASC score ≥12, indicating a more severe phenotype. Furthermore, comparing PASC positive (score ≥12) vs. PASC 264 265 indeterminate subjects (score <12) reinfection rates and symptom clustering occurred most frequently in PASC positive subjects (Supplementary Material); interestingly, lower 266 267 vaccination and infections detected during periods of Omicron variant predominance were 268 observed in PASC positive vs. PASC indeterminate individuals. This indicated that the 269 PASC score likely detected individuals with a more severe PASC phenotype.

270 <u>PASC prevalence in selected subgroups</u>

PASC prevalence estimates generally increased with age and were higher in females 271 272 compared to males (Figure 2B); furthermore, PASC prevalence was higher with 273 increasing DISLI values, particularly in urban settings (Figure 2D). For infection-related 274 variables the prevalence of PASC was lower if the last infection occurred during periods of 275 high Omicron variant circulation compared to other SARS-CoV-2 variants and was 276 generally lower in vaccinated subjects irrespective of variant predominance (Figure 2C); 277 similarly, prevalence of PASC was higher in subjects with at least one reinfection 278 compared to primoinfection, but this was more evident in cases where COVID-19 was 279 acquired during periods of Omicron variant predominance (Figure 2E). Finally, when

evaluating PASC prevalence per year at which the last SARS-CoV-2 infection was diagnosed, prevalence changed from 25.82% (95%CI 22.40-29.24) for cases infected in 2020, to 21.96% for cases infected in 2021 (95%CI 19.65-24.27), and to 17.60% (95%CI

283 15.36-19.84) for cases infected in 2022 (**Supplementary Material**).

284 <u>Modifiers of PASC prevalence</u>

We fitted fixed effects logistic regression model considering survey weights to identify 285 correlates of PASC positivity amongst individuals with previously diagnosed COVID-19 286 and complete data including comorbidities (n=2,504). We identified that infection during 287 periods of Omicron variant predominance (OR 0.73, 95%CI 0.59-0.90) and male sex (OR 288 0.75, 95%CI 0.61-0.91) were associated with lower odds of PASC positivity. In addition, 289 290 having had at least one SARS-CoV-2 reinfection (OR 1.83, 95%CI 1.38-2.41), having 291 moderate to severe depressive symptoms as identified by CES-D (OR 1.89, 95%CI 1.51-2.36), older age, and living in states with higher social lag (OR 1.48, 95%CI 1.10-1.99 for 292 293 Q4 vs Q1) were associated with higher odds of PASC positivity (Figure 3A). When 294 evaluating the same predictors but using the definition of PASC score ≥ 12 points, which likely indicates a more severe PASC phenotype, infection during periods of Omicron 295 variant predominance, COVID-19 vaccination, having had at least one SARS-CoV-2 296 reinfection, living in states with higher social lag, and moderate to severe depressive 297 298 symptoms by CES-D were associated with the outcome (Figure 3B); further disaggregating by the number of vaccine doses compared to unvaccinated individuals 299 showed a similar protective effect with increasing doses and irrespective of vaccine 300 301 platform for primary vaccination schedule (Supplementary Material).

302 <u>Predictors of incapacitating PASC symptoms</u>

Amongst individuals with persistent symptoms a PASC score ≥12 points resulted in higher
 rates of incapacitating symptoms at all time points and independent of the WHO PASC

305 definition (Figure 4A). Predictors of incapacitating symptoms included previously diagnosed diabetes (OR 1.98, 95%CI 1.00-3.90), moderate to severe depressive 306 307 symptoms (OR 1.85, 95%CI 1.07-3.20), age 50-59 years compared to younger individuals 308 (OR 3.39, 95%CI 1.32-10.37), having had at least one SARS-CoV-2 reinfection (OR 2.58, 95%CI 1.24-5.31) and a lower risk observed in individuals infected during periods of 309 310 Omicron variant predominance (OR 0.42, 95%CI 0.22-0.79). Notably, the most significant predictor of incapacitating PASC symptoms was a PASC score ≥12 points (OR 4.92, 311 312 95%CI 2.37, 10.12).

313 **DISCUSSION**

314 Here, we conducted the first comprehensive report on the prevalence of PASC in Mexican 315 adults during the year 2022, surveying a total of 24,434 participants. Persistent COVID-19 316 symptoms were reported by 12.44% of adults ≥20 years in Mexico and amongst 12.7% of 317 adults with SARS-CoV-2 N-protein seropositivity during 2022. The most commonly 318 reported persistent COVID-19 symptoms amongst SARS-CoV-2 N-protein seropositive 319 adults include musculoskeletal pain, followed by headache, cough, loss of smell or taste, fever, post-exertional malaise, brain fog, anxiety, chest pain, and sleep disorders. Using a 320 recent the WHO PASC definition (3) we identified a prevalence of 5.51% amongst SARS-321 322 CoV-2 N-protein seropositive Mexican adults and 21.21% amongst cases with previously 323 diagnosed COVID-19; the prevalence of PASC increased with age and was higher for females, for SARS-CoV-2 infections detected in 2020 and in settings with higher social lag 324 in urban settings. PASC was associated with increasing number of SARS-CoV-2 325 326 reinfections, moderate to severe depressive symptoms and living in states burdened by 327 sociodemographic inequalities. We also confirm previous reports that COVID-19 328 vaccination and infection during periods of Omicron variant predominance decreases odds of severe forms of PASC (2,22,23). Notably, over 28.6% patients with PASC reported 329

330 persistence of symptoms over 6 months and over 14.06% reported incapacitating 331 symptoms, which indicate a subset of participants in whom interventions may lead to a 332 significant improvement in quality of life (24). Finally, we identified that incapacitating 333 PASC symptoms were associated with diabetes, moderate to severe depressive symptoms, SARS-CoV-2 reinfections and a PASC score ≥12 points. Our study represents 334 335 the first comprehensive and nationally representative report of PASC in Mexican adults 336 and the first report on the impact of vaccination, SARS-CoV-2 variants, reinfections, and 337 sociodemographic inequalities in the prevalence of PASC and symptom persistence and 338 severity in Mexico.

A previous systematic review identified that approximately 72.5% of individuals previously 339 340 infected by SARS-CoV-2 experienced post-acute sequelae (25). This contrasts with a 341 lower reported prevalence of 56.52% amongst individuals with previously diagnosed COVID-19 reported in our study and with the even lower estimate amongst SARS-CoV-2 342 343 seropositive adults. A previous study using data from ENSANUT 2020 reported that 344 amongst SARS-CoV-2 seropositive individuals who recovered from COVID-19 in Mexico. approximately 15.7% reported unspecified sequelae, with these being higher in females, 345 346 older adults and hospitalized individuals (11). In our study, we identified that the main 347 predictors of higher PASC prevalence include SARS-CoV-2 reinfections, moderate to 348 severe depressive symptoms and sociodemographic inequalities as proxied by the DISLI. Similar to our findings, previous reports from the UK showed that individuals with PASC 349 clustered in areas of higher socioeconomic deprivation (26), supporting the notion that 350 structural determinants of health may influence the incidence and natural history of chronic 351 352 debilitating diseases including chronic fatigue syndrome, myalgic encephalitis and PASC (27,28), as it does during the acute phase of SARS-CoV-2 infection (9). Our findings are 353 also in agreement with previous data supporting that SARS-CoV-2 reinfections increased 354

the risk of SARS-CoV-2 sequelae, irrespective of predominant variant; although, lower risk of PASC has been consistently associated with infections caused by the Omicron compared to previous circulating variants (29,30). Finally, the higher rate of moderate to severe depressive symptoms and self-reported anxiety in PASC indicates a relevant area of intervention for affected individuals, particularly since long-term neuropsychiatric sequelae has been consistently reported in SARS-CoV-2 convalescent individuals after recovery from acute infection (4,14,31–33).

The precise nature behind the pathophysiology of PASC is unclear. Current evidence 362 363 suggests involvement of SARS-CoV-2 mediated pathophysiological changes in several tissues, immune system dysregulation and immune response viral particle persistence and 364 365 expected sequelae of critical illness. Increased inflammatory responses and an inadequate 366 adaptation of the hypothalamic-pituitary-adrenal axis to hypocortisolemia after acute SARS-CoV-2 infection may underlie the occurrence of symptoms related to brain fog, post-367 368 exertional malaise, and neuropsychiatric symptoms, including anxiety and depression in 369 PASC positive patients (2,34–36), which often last the longest in patients with persistent COVID-19 symptoms (10,37). Consistent with findings from our study, previous data has 370 371 shown that COVID-19 vaccination decreases the risk of PASC and persistent COVID-19 372 sequelae (23,38); the mechanism underlying this association is unclear. A previous 373 immune phenotyping study of PASC identified increased levels of anti-N and anti-S IgG in individuals with PASC compared to vaccinated controls, indicating persistent chronic 374 immune responses to SARS-CoV-2 viral antigens in PASC, which may be modulated in 375 376 response to COVID-19 vaccination (34). In agreement with our findings for severe PASC 377 phenotypes, longitudinal evaluations have shown that increasing number of COVID-19 378 vaccine doses are associated with symptom improvement over time (1,39); however, some studies have suggested that a subset of participants may not experience 379

improvement or may even experience worsening of symptoms after vaccination (40).
 Further evidence is required to investigate the impact of COVID-19 vaccinations after
 reinfections, which have been shown to be reduced themselves by booster vaccination
 (15).

Our study had several strengths including a nationally representative sample of individuals 384 385 with antibody measurement to detect SARS-CoV-2 N-protein seropositivity, previously diagnosed COVID-19 and reports of long-term sequelae. Furthermore, we were able to 386 387 assess risk factors related to state-level sociodemographic inequalities, vaccination, reinfection, and predominant variant at the time of infection to explore correlates of PASC 388 in a representative sample of Mexican adults. However, some limitations must be 389 390 acknowledged to adequately interpret our results. Since the definition of PASC is still 391 evolving, we applied two main definitions based on the World Health organization consensus and a recent definition based on a symptom score (3,4). Despite the 392 393 robustness of incorporating several definitions of PASC, we were unable to include all 394 symptoms evaluated in the PASC score and symptoms and post-COVID-19 conditions reported in other studies including palpitations, chronic thirst, decreased sexual desire or 395 396 capacity, abnormal movements, new-onset diabetes, and cardiovascular events including 397 coagulopathy and thrombosis, some of which have previously been reported for cases 398 recovered from severe COVID-19 in Mexico (10); this may lead to an underestimation in the prevalence of severe PASC using this measure and its impact on patients' health. 399 Next, we used SARS-CoV-2 N-protein seropositivity as a proxy of previous SARS-CoV-2 400 infection given the high rates of undetected asymptomatic SARS-CoV-2 infections in 401 402 Mexico, which may otherwise lead to an underestimation of PASC prevalence (41,42). However, a subset of participants who received the CoronaVac inactivated virus vaccine 403 may display seropositivity despite not having been previously infected, this represents 404

405 9.44% (95%CI 10.63-11.97) of the total SARS-CoV-2 N-protein seropositive population 406 (43,44). To address this, we also conducted an analysis excluding individuals who 407 received with CoronaVac and individuals who had COVID-19 previously diagnosed by a 408 physician, obtaining largely similar results with slightly lower prevalence estimates (Supplementary Material). Finally, although the observed associations are consistent 409 410 with data from previous studies, its observational nature precludes from making temporal associations with the incidence of PASC, which require further studies to further support 411 412 these findings in Mexican population.

413 Conclusion

414 We report a prevalence of PASC of 4.67% in the general population, affecting 21.21% of 415 individuals with previously diagnosed COVID-19. In general, over 12.44% of Mexican 416 adults report at least one persistent COVID-19 symptom, with the most common being 417 musculoskeletal pain, headache, cough, loss of smell or taste, and fever. PASC 418 prevalence increased with age and was more common in females; severe PASC was less 419 frequent for cases infected during periods of Omicron variant predominance and in vaccinated individuals in a dose-dependent manner but was more common in individuals 420 with at least one detected SARS-CoV-2 reinfection. Moreover, prevalence of PASC 421 422 increased in states with higher marginalization, particularly in urban settings. Of note, over 423 14.05% of participants affected by PASC reported trouble in everyday physical functioning, highlighting the disabling nature of persistent symptoms and indicating a need to 424 implement multidisciplinary teams for patient treatment in Mexico. Further studies are 425 required to characterize the epidemiology of PASC in Mexico using standardized 426 427 definitions and with longer follow-up in order to identify strategies to mitigate its long-term 428 impact in physical functioning and quality of life as SARS-CoV-2 transitions into endemicity. 429

430

431 ACKNOWLEDGMENTS

- 432 CAFM is enrolled at the PECEM Program of the Faculty of Medicine at UNAM. CAFM and
- 433 DRG are supported by CONACyT.

434 AUTHOR CONTRIBUTIONS

- 435 Research idea and study design: OYBC, CAFM; data acquisition and processing: CAFM,
- 436 NEAV, OYBC; statistical analysis: OYBC; analysis/interpretation: CDPC, CAFM, OYBC,
- 437 NEAV, AVV, LFC, DRG; manuscript drafting: OYBC, CAFM, DRG, LFC, AVV, MRBA,
- 438 PSC, ANL, NEAV; supervision or mentorship: OYBC, NEAV. Each author contributed
- 439 important intellectual content during manuscript drafting or revision and accepts
- 440 accountability for the overall work by ensuring that questions pertaining to the accuracy or
- integrity of any portion of the work are appropriately investigated and resolved.
- 442 **DATA AVAILABILITY:** All code, datasets and materials are available for reproducibility of
- 443 results at http://github.com/oyaxbell/pasc_ensanut/. ENSANUT 2022 data is openly
- 444 available at: <u>https://ensanut.insp.mx/encuestas/ensanutcontinua2022/descargas.php</u>
- 445 **CONFLICT OF INTEREST/FINANCIAL DISCLOSURE:** Nothing to disclose.
- 446 **FUNDING:** This research was supported by Instituto Nacional de Geriatría in Mexico.
- 447
- 448

449 **REFERENCES**

- 1. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings,
- 451 mechanisms and recommendations. Nat Rev Microbiol. 2023 Mar;21(3):133–46.
- 452 2. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al.
- 453 Attributes and predictors of long COVID. Nat Med. 2021 Apr;27(4):626–31.
- 454 3. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case

455	Definit	ion Working Group on Post-COVID-19 Condition. A clinical case definition of post-
456	COVIE	0-19 condition by a Delphi consensus. Lancet Infect Dis. 2022 Apr;22(4):e102–7.
457	4.	Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al.
458	Develo	opment of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA. 2023
459	Jun 13	;329(22):1934–46.
460	5.	Sakhamuri SM, Jankie S, Pereira LMP. Calling on Latin America and the
461	Caribb	ean countries to recognise the disability from long COVID. The Lancet Regional
462	Health	- Americas [Internet]. 2022 Nov 1 [cited 2023 Jul 4];15. Available from:
463	https://	/www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00179-X/fulltext
464	6.	Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, et al.
465	Corona	avirus Pandemic (COVID-19). Our World in Data [Internet]. 2020 Mar 5 [cited 2023
466	Jul 4];	Available from: https://ourworldindata.org/coronavirus/country/mexico
467	7.	Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A,
468	Gonzá	lez-Díaz A, Márquez-Salinas A, et al. Predicting Mortality Due to SARS-CoV-2: A
469	Mecha	nistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico. The
470	Journa	I of Clinical Endocrinology & Metabolism. 2020 Aug 1;105(8):2752–61.
471	8.	Bello-Chavolla OY, Antonio-Villa NE, Valdés-Ferrer SI, Fermín-Martínez CA,
472	Fernár	ndez-Chirino L, Vargas-Vázquez A, et al. Effectiveness of a nationwide COVID-19
473	vaccin	ation program in Mexico against symptomatic COVID-19, hospitalizations, and
474	death:	a retrospective analysis of national surveillance data. Int J Infect Dis. 2023
475	Apr;12	9:188–96.
476	9.	Antonio-Villa NE, Fernandez-Chirino L, Pisanty-Alatorre J, Mancilla-Galindo J,
477	Kamm	ar-García A, Vargas-Vázquez A, et al. Comprehensive evaluation of the impact of
478	sociod	emographic inequalities on adverse outcomes and excess mortality during the
479	COVIE	0-19 pandemic in Mexico City. Clin Infect Dis. 2021 Jun 22;ciab577.

- 480 10. Núñez I, Gillard J, Fragoso-Saavedra S, Feyaerts D, Islas-Weinstein L, Gallegos-
- 481 Guzmán AA, et al. Longitudinal Clinical Phenotyping of Post COVID Condition in Mexican
- 482 Patients Recovering from Severe COVID-19: A Prospective Cohort Study [Internet].
- 483 Rochester, NY; 2022 [cited 2023 Jul 4]. Available from:
- 484 https://papers.ssrn.com/abstract=4238650
- 485 11. Vidaña-Pérez D, López-Olmedo N, González-Morales R, Shamah-Levy T,
- 486 Barrientos-Gutiérrez T. Prevalence of Covid-19 sequelae in the National Health and
- 487 Nutrition Survey 2020. Salud Pública de México. 2021 Oct 25;63(6, Nov-Dic):799–802.
- 488 12. Romero-Martínez M, Barrientos-Gutiérrez T, Cuevas-Nasu L, Bautista-Arrendondo
- 489 S, Colchero MA, Gaona-Pineda EB, et al. Metodología de la Encuesta Nacional de Salud
- 490 y Nutrición 2022 y Planeación y diseño de la Ensanut Continua 2020-2024. Salud Pública
- 491 de México. 2022 Aug 26;64(5, sept-oct):522–9.
- 492 13. Sánchez-Pájaro A, Ferrer CP, Basto-Abreu A, Rivera-Dommarco J, Barquera S,
- 493 Denova-Gutiérrez E, et al. Seroprevalencia de SARS-CoV-2 en adultos y adultos mayores
- 494 en México y su asociación con enfermedades crónicas. Ensanut 2020 Covid-19. Salud
- 495 Pública de México. 2021 Nov 5;63(6, Nov-Dic):705–12.
- 496 14. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al.
 497 Post-acute COVID-19 syndrome. Nat Med. 2021 Apr:27(4):601–15.
- 498 15. Montes-González JA, Zaragoza-Jiménez CA, Antonio-Villa NE, Fermín-Martínez
- 499 CA, Ramírez-García D, Vargas-Vázquez A, et al. Protection of hybrid immunity against
- 500 SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant
- predominance in Mexico. Front Public Health. 2023;11:1146059.
- 16. Indice Rezago Social 2020 [Internet]. [cited 2023 Jul 1]. Available from:
- 503 https://www.coneval.org.mx/Medicion/IRS/Paginas/Indice_Rezago_Social_2020.aspx
- 17. Antonio-Villa NE, Bello-Chavolla OY, Fermín-Martínez CA, Aburto JM, Fernández-

- 505 Chirino L, Ramírez-García D, et al. Socio-demographic inequalities and excess non-
- 506 COVID-19 mortality during the COVID-19 pandemic: a data-driven analysis of 1 069 174
- 507 death certificates in Mexico. Int J Epidemiol. 2022 Dec 13;51(6):1711–21.
- 18. Bello-Chavolla OY, Antonio-Villa NE, Fermín-Martínez CA, Fernández-Chirino L,
- 509 Vargas-Vázquez A, Ramírez-García D, et al. Diabetes-Related Excess Mortality in Mexico:
- 510 A Comparative Analysis of National Death Registries Between 2017–2019 and 2020.
- 511 Diabetes Care. 2022 Oct 26;45(12):2957–66.
- 512 19. Salinas-Rodríguez A, Manrique-Espinoza B, Acosta-Castillo GI, Franco-Núñez A,
- 513 Rosas-Carrasco O, Gutiérrez-Robledo LM, et al. [Validation of a cutoff point for the short
- version of the Depression Scale of the Center for Epidemiologic Studies in older Mexican
- adults]. Salud Publica Mex. 2014;56(3):279–85.
- 516 20. Salinas-Rodríguez A, Manrique-Espinoza B, Acosta-Castillo I, Téllez-Rojo MM,
- 517 Franco-Núñez A, Gutiérrez-Robledo LM, et al. [Validation of a cutoff for the Depression
- 518 Scale of the Center for Epidemiologic Studies, Brief Version (CESD-7)]. Salud Publica
- 519 Mex. 2013;55(3):267–74.
- 520 21. survey.pdf [Internet]. [cited 2023 Apr 21]. Available from: https://cran.r-
- 521 project.org/web/packages/survey/survey.pdf
- 522 22. Tran VT, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of COVID-19
- 523 Vaccination on the Symptoms of Patients With Long COVID: A Target Trial Emulation
- 524 Using Data From the ComPaRe e-Cohort in France [Internet]. Rochester, NY: Social
- 525 Science Research Network; 2021 Sep [cited 2021 Oct 7]. Report No.: ID 3932953.
- 526 Available from: https://papers.ssrn.com/abstract=3932953
- 527 23. Brannock MD, Chew RF, Preiss AJ, Hadley EC, Redfield S, McMurry JA, et al.
- 528 Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the
- 529 RECOVER program. Nat Commun. 2023 May 22;14(1):2914.

- 530 24. Ballouz T, Menges D, Anagnostopoulos A, Domenghino A, Aschmann HE, Frei A,
- et al. Recovery and symptom trajectories up to two years after SARS-CoV-2 infection:
- population based, longitudinal cohort study. BMJ. 2023 May 31;381:e074425.
- 533 25. Nasserie T, Hittle M, Goodman SN. Assessment of the Frequency and Variety of
- 534 Persistent Symptoms Among Patients With COVID-19: A Systematic Review. JAMA Netw
- 535 Open. 2021 May 3;4(5):e2111417.
- 536 26. Shabnam S, Razieh C, Dambha-Miller H, Yates T, Gillies C, Chudasama YV, et al.
- 537 Socioeconomic inequalities of Long COVID: a retrospective population-based cohort study
- 538 in the United Kingdom. J R Soc Med. 2023 May 10;1410768231168377.
- 539 27. Collin SM, Bakken IJ, Nazareth I, Crawley E, White PD. Trends in the incidence of
- 540 chronic fatigue syndrome and fibromyalgia in the UK, 2001-2013: a Clinical Practice
- 541 Research Datalink study. J R Soc Med. 2017 Jun;110(6):231–44.
- 542 28. BERGER Z, ALTIERY DE JESUS V, ASSOUMOU SA, GREENHALGH T. Long
- 543 COVID and Health Inequities: The Role of Primary Care. Milbank Q. 2021 Jun;99(2):519–
- 544 41.
- 545 29. Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-
- 546 CoV-2 reinfection. Nat Med. 2022 Nov;28(11):2398–405.
- 547 30. Doll MK, Waghmare A, Heit A, Levenson Shakoor B, Kimball LE, Ozbek N, et al.
- 548 Acute and Postacute COVID-19 Outcomes Among Immunologically Naive Adults During
- 549 Delta vs Omicron Waves. JAMA Network Open. 2023 Feb 28;6(2):e231181.
- 550 31. Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, et al. Anxiety and
- depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain
- 552 Behav Immun. 2020 Oct;89:594–600.
- 553 32. Postolache TT, Benros ME, Brenner LA. Targetable Biological Mechanisms
- 554 Implicated in Emergent Psychiatric Conditions Associated With SARS-CoV-2 Infection.

555 JAMA Psychiatry. 2020 Jul 31;

- 556 33. Villalpando JMG, Forcelledo HA, Castillo JLB, Sastré AJ, Rojop IEJ, Hernández
- 557 VO, et al. COVID-19, Long COVID Syndrome, and Mental Health Sequelae in a Mexican
- 558 Population. Int J Environ Res Public Health. 2022 Jun 7;19(12):6970.
- 559 34. Klein J, Wood J, Jaycox J, Lu P, Dhodapkar RM, Gehlhausen JR, et al.
- 560 Distinguishing features of Long COVID identified through immune profiling [Internet].
- 561 medRxiv; 2022 [cited 2023 Jul 4]. p. 2022.08.09.22278592. Available from:
- 562 https://www.medrxiv.org/content/10.1101/2022.08.09.22278592v1
- 563 35. PHOSP-COVID Collaborative Group. Clinical characteristics with inflammation
- profiling of long COVID and association with 1-year recovery following hospitalisation in
- the UK: a prospective observational study. Lancet Respir Med. 2022 Aug;10(8):761–75.
- 566 36. Yavropoulou MP, Tsokos GC, Chrousos GP, Sfikakis PP. Protracted stress-
- 567 induced hypocortisolemia may account for the clinical and immune manifestations of Long
- 568 COVID. Clin Immunol. 2022 Dec;245:109133.
- 569 37. Hastie CE, Lowe DJ, McAuley A, Mills NL, Winter AJ, Black C, et al. Natural history
- of long-COVID in a nationwide, population cohort study. Nat Commun. 2023 Jun
- 571 13;14(1):3504.
- 572 38. Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P. Effect of covid-19
- 573 vaccination on long covid: systematic review. BMJ Medicine [Internet]. 2023 Feb 1 [cited
- 574 2023 Jul 4];2(1). Available from: https://bmjmedicine.bmj.com/content/2/1/e000385
- 39. Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Nafilyan V, Zaccardi F,
- 576 et al. Trajectory of long covid symptoms after covid-19 vaccination: community based
- 577 cohort study. BMJ. 2022 May 18;377:e069676.
- 40. Tsuchida T, Hirose M, Inoue Y, Kunishima H, Otsubo T, Matsuda T. Relationship between changes in symptoms and antibody titers after a single vaccination in patients

580 with Long COVID. J Med Virol. 2022 Jul;94(7):3416–20.

- 581 41. Bello-Chavolla OY, Antonio-Villa NE, Fernández-Chirino L, Guerra EC, Fermín-
- 582 Martínez CA, Márquez-Salinas A, et al. Diagnostic performance and clinical implications of
- rapid SARS-CoV-2 antigen testing in Mexico using real-world nationwide COVID-19
- registry data. PLOS ONE. 2021 Aug 31;16(8):e0256447.
- 585 42. Bello-Chavolla OY, Antonio-Villa NE, Vargas-Vázquez A, Fermín-Martínez CA,
- 586 Márquez-Salinas A, Bahena-López JP. Profiling Cases With Nonrespiratory Symptoms
- and Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections in
- 588 Mexico City. Clin Infect Dis. 2021 May 18;72(10):e655–8.
- 43. Rosa Duque JS, Wang X, Leung D, Cheng SMS, Cohen CA, Mu X, et al.
- 590 Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac
- in healthy adolescents. Nat Commun. 2022 Jun 28;13(1):3700.
- 592 44. Fonseca MHG, Pinto ACMD, Silva MFS, de Melo ACL, Vasconcelos GS, dos
- 593 Santos ER, et al. Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by
- Booster Dose of BNT162b2 Vaccine. Emerg Infect Dis. 2022 Jun;28(6):1237–40.

595


597 **<u>TABLES</u>**

- 598 TABLE 1. Sociodemographic and clinical characteristics of individuals with post-acute
- 599 sequelae of SARS-CoV-2 symptoms (PASC) as defined by the World Health Organization
- 600 compared individuals without PASC and previously diagnosed with COVID-19 in the
- 601 ENSANUT 2022 sample.

		Overall Sampl	е	•
Characteristic	Overall, N = 5,211 ¹	PACS indeterminate, $N = 4,161^{1}$	PACS positive, N = 1,050 ¹	p-value ²
Male sex (%)	2,322 (45%)	1,934 (46%)	388 (37%)	<0.001
Age (years)	43 (31, 55)	42 (30, 54)	47 (35, 57)	<0.001
Reinfection (%)	638 (12%)	465 (11%)	173 (16%)	<0.001
Omicron variant (%)	2,087 (40%)	1,716 (41%)	371 (35%)	<0.001
COVID-19 vaccine (%)	4,830 (93%)	3,843 (92%)	987 (94%)	0.068
Symptom duration	,			<0.001
<1 month	1,363 (47%)	1,363 (74%)	0 (0%)	
1-3 months	478 (17%)	478 (26%)	0 (0%)	
3-6 months	124 (4.3%)	0 (0%)	124 (12%)	
>6 months	126 (4.4%)	0 (0%)	126 (12%)	
Still persistent	800 (28%)	0 (0%)	800 (76%)	
Any symptom (%)	2,839 (54%)	1,793 (43%)	1,046 (100%)	<0.001
Loss of smell/taste (%)	692 (13%)	501 (12%)	191 (18%)	< 0.001
Brain fog (%)	166 (3.2%)	74 (1.8%)	92 (8.8%)	< 0.001
Gastrointestinal	160 (3.1%)	119 (2.9%)	41 (3.9%)	0.079
symptoms (%)	(,)	(,	(0.0,0)	
Chest pain (%)	285 (5.5%)	170 (4.1%)	115 (11%)	<0.001
Breathlessness (%)	358 (6.9%)	198 (4.8%)	160 (15%)	< 0.001
Dyspnea (%)	513 (9.8%)	283 (6.8%)	230 (22%)	< 0.001
Musculoskeletal pain (%)	913 (18%)	617 (15%)	296 (28%)	< 0.001
Dizziness (%)	213 (4.1%)	130 (3.1%)	83 (7.9%)	<0.001
Headache (%)	817 (16%)	575 (14%)	242 (23%)	< 0.001
Weight loss (%)	203 (3.9%)	149 (3.6%)	54 (5.1%)	0.019
Loss of appetite (%)	203 (3.9%) 210 (4.0%)	169 (4.1%)	41 (3.9%)	0.013
Kidney problems (%)	55 (1.1%)	30 (0.7%)	25 (2.4%)	<0.001
Sleep disturbances (%)	288 (5.5%)	169 (4.1%)	119 (11%)	<0.001
Fever (%)	670 (13%)	608 (15%)	62 (5.9%)	< 0.001
Depression (%)		117 (2.8%)	70 (6.7%)	< 0.001
	187 (3.6%)	. ,		
Anxiety (%)	256 (4.9%) 1,250 (24%)	145 (3.5%)	111 (11%)	< 0.001
Fatigue (%)		783 (19%)	467 (44%)	< 0.001
Chronic cough (%)	978 (19%)	737 (18%)	241 (23%)	< 0.001
Post-exertional malaise	541 (10%)	342 (8.2%)	199 (19%)	<0.001
(%) BASC sooro			20(100)	10 004
PASC score	0.0 (0.0, 5.0)	0.0 (0.0, 4.0)	3.0 (1.0, 8.0)	< 0.001
DISLI quartile	1 707 (220/)	1 420 (240/)	077 (060/)	<0.001
Q1	1,707 (33%)	1,430 (34%)	277 (26%)	
Q2	1,630 (31%)	1,304 (31%)	326 (31%)	
Q3	965 (19%)	721 (17%)	244 (23%)	
Q4	909 (17%)	706 (17%)	203 (19%)	0.001
CES-D score	5.0 (3.0, 8.0)	5.0 (3.0, 7.0)	6.0 (4.0, 9.0)	< 0.001
Diabetes (%)	358 (14%)	258 (13%)	100 (17%)	0.015
Hypertension (%)	505 (20%)	357 (18%)	148 (26%)	<0.001
Daily smoking (%)	178 (7.1%)	140 (7.3%)	38 (6.6%)	0.6
Vaccine type				0.091
Linvooinotod	381 (7.3%)	318 (7.6%)	63 (6.0%)	
Unvaccinated mRNA	1,607 (31%)	1,291 (31%)	316 (30%)	

		Overall Sampl	e	
Characteristic	Overall, N = 5,211 ¹	PACS indeterminate, $N = 4,161^{1}$	PACS positive, N = 1,050 ¹	p-value ²
Adenovirus vector	2,629 (50%)	2,075 (50%)	554 (53%)	
Inactivated virus	438 (8.4%)	344 (8.3%)	94 (9.0%)	
Other	156 (3.0%)	133 (3.2%)	23 (2.2%)	
Incapacitating	457 (8.8%)	310 (7.5%)	147 (14%)	<0.001
symptoms		. ,		

²Pearson's Chi-squared test; Wilcoxon rank sum test; Fisher's exact test






602

Figure 1. Prevalence of persistent COVID-19 symptoms amongst SARS-CoV-2 N-protein seropositive adults \geq 20 years in ENSANUT 2022 (**A**) and prevalence of post-acute sequelae of SARS-CoV-2 symptoms (PASC) as identified by a PASC score \geq 12 in the overall population, in SARS-CoV-2 N-protein seropositive adults and in individuals with COVID-19 previously diagnosed by a physician in the ENSANUT 2022 sample (**B**).


608



Prevalence of post-acute sequelae of SARS-CoV-2 symptoms (PASC) as 611 Figure 2. 612 identified by a PASC score ≥12 stratified by geographical regions in Mexico within the ENSANUT 2022 sample of adults \geq 20 years (**A**). The figure also shows PASC prevalence 613 614 stratified by age and sex categories (B), by predominant circulating variant at the time of 615 last SARS-CoV-2 infection and vaccination status (C), by density-independent social lag 616 index (DISLI) guartiles in rural vs. urban setting (D), and in subjects with primoinfection 617 compared to at least one SARS-CoV-2 reinfection during periods of non-Omicron and Omicron variant (E). 618 predominance

Variable		N	Odds ratio		р	B Variable		N	Odds ratio		р
Omicron variant		2504	-	0.73 (0.59, 0.90)	0.004	Omicron variant		2504	H a h	0.65 (0.48, 0.88)	0.006
Age (years)	20-29	496		Reference		Age (years)	20-29	496	÷	Reference	
	30-39	508	⊨∎-	1.39 (1.02, 1.91)	0.038		30-39	508	⊢∎¦-	0.76 (0.50, 1.16)	0.207
	40-49	521	⊢ ∎-י	1.67 (1.20, 2.32)	0.002		40-49	521	-	1.12 (0.73, 1.72)	0.589
	50-59	509		2.45 (1.76, 3.43)	<0.001		50-59	509	- - -	0.76 (0.47, 1.22)	0.262
	60-69	295	- -	1.85 (1.24, 2.75)	0.003		60-69	295	⊢ ∎+	0.63 (0.34, 1.14)	0.139
	≥70	175	- 	0.88 (0.50, 1.50)	0.648		≥70	175	- -	0.87 (0.43, 1.72)	0.700
Male sex		2504	-	0.75 (0.61, 0.91)	0.004	Male sex		2504	-	1.23 (0.93, 1.64)	0.151
Vaccinated		2504	- -	0.92 (0.62, 1.39)	0.681	Vaccinated		2504	-	0.38 (0.25, 0.59)	<0.001
Reinfection		2504	⊢ ∎-	1.83 (1.38, 2.41)	<0.001	Reinfection		2504		1.73 (1.15, 2.54)	0.007
Diabetes		2504	⊢ ∰	0.95 (0.70, 1.28)	0.729	Diabetes		2504	-	1.44 (0.95, 2.14)	0.080
Hypertension		2504	, i n in the second s	1.16 (0.89, 1.50)	0.273	Hypertension		2504	- -	1.27 (0.87, 1.84)	0.204
Daily smoking		2504	- -	1.04 (0.70, 1.51)	0.856	Daily smoking		2504	÷=-	1.53 (0.93, 2.44)	0.083
Depressive symptoms		2504	·=·	1.89 (1.51, 2.36)	<0.001	Depressive symptoms		2504	¦∎•	1.40 (1.01, 1.92)	0.039
DISLI	Q1	819	, 🛉	Reference		DISLI	Q1	819		Reference	
	Q2	787	i∎•	1.27 (0.99, 1.65)	0.065		Q2	787	, I∎-	2.08 (1.43, 3.06)	<0.001
	Q3	453	·-	1.72 (1.29, 2.29)	<0.001		Q3	453		1.69 (1.07, 2.64)	0.023
	Q4	445	⊢ ∎-1	1.48 (1.10, 1.99)	0.009		Q4	445		2.24 (1.45, 3.45)	<0.001
Setting	Urban	2134	•	Reference		Setting	Urban	2134		Reference	
	Rural	370	r∎r	0.83 (0.61, 1.11)	0.215		Rural	370	-	0.81 (0.53, 1.21)	0.320
Education	Primary or less	471	, 📫	Reference		Education	Primary or less	471	÷.	Reference	
	Secondary	619	⊢ ∎ ¦	0.81 (0.59, 1.13)	0.220		Secondary	619		1.28 (0.81, 2.05)	0.287
	High school or technical	625	-	0.90 (0.64, 1.26)	0.529		High school or technical	625	-	0.92 (0.56, 1.51)	0.739
	University or higher	789	⊷ ∎ ÷	0.78 (0.56, 1.09)	0.145		University or higher	789	- -	0.80 (0.49, 1.33)	0.389

FIGURE 3. Fixed effects logistic regression model adjusted by survey weights for prediction of post-acute sequelae of SARS-CoV-2 symptoms (PASC) identified by a PASC score \geq 12 (**A**) and the presence of any persistent COVID-19 symptom (**B**) amongst Mexican adults enrolled in ENSANUT 2022. <u>Abbreviations:</u> DISLI, Density-independent social lag-index; Depressive symptoms: Moderate to severe depressive symptoms identified by the Center for Epidemiologic Studies Depression Scale.



Variable		N	Odds ratio		р
Omicron variant		574		0.42 (0.22, 0.79)	0.009
Age (years)	20-29	77		Reference	
	30-39	102	·	2.14 (0.80, 6.36)	0.144
	40-49	128	- H	1.19 (0.41, 3.69)	0.757
	50-59	149		3.49 (1.32, 10.37)	0.017
	60-69	82		1.73 (0.53, 5.91)	0.370
	≥70	36		1.52 (0.31, 6.95)	0.592
Male sex		574	- 	0.75 (0.42, 1.30)	0.310
Vaccinated		574		1.65 (0.57, 6.03)	0.398
Reinfection		574		2.58 (1.24, 5.31)	0.010
Diabetes		574		1.98 (0.99, 3.90)	0.049
Hypertension		574	- -	0.91 (0.47, 1.74)	0.789
Daily smoking		574		1.41 (0.47, 3.72)	0.513
Depressive symptoms		574	- -	1.85 (1.07, 3.20)	0.028
DISLI	Q1	155	i i	Reference	
	Q2	189	i-i∎i	1.53 (0.77, 3.10)	0.229
	Q3	127	⊢∎¦-	0.57 (0.23, 1.34)	0.207
	Q4	103	⊷∎⊷	1.52 (0.71, 3.31)	0.283
Setting	Urban	487		Reference	
	Rural	87	- -	0.79 (0.32, 1.78)	0.583
Education	Primary or less	130	•	Reference	
	Secondary	145	- -	0.87 (0.37, 2.01)	0.742
	High school or technical	145		0.73 (0.31, 1.71)	0.466
	University or higher	154	⊷∎⊷	1.39 (0.60, 3.25)	0.445
PASC score	<12	520		Reference	
	≥12	54		4.91 (2.37, 10.12)	<0.001

FIGURE 4. Prevalence of incapacitating symptoms amongst patients with persistent post-626 627 COVID-19 sequelae disaggregated by PASC scores using a 12-point threshold (A). The 628 figure also shows a fixed effects logistic regression model adjusted by survey weights for

- 629 prediction of debilitating PASC symptoms (A) and the presence of any persistent COVID-
- 630 19 symptom (B) amongst Mexican adults enrolled in ENSANUT 2022. Abbreviations:
- 631 PASC, Post-acute sequelae of SARS-CoV-2 infection; DISLI, Density-independent social
- 632 lag-index; Depressive symptoms: Moderate to severe depressive symptoms identified by
- 633 the Center for Epidemiologic Studies Depression Scale.
- 634